ClinicalTrials.gg
RecruitingNCT07070479Updated Sep 18, 2025

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

A Phase 2 interventional study of Ivonescimab and Nimotuzumab in Recurrent or Metastatic Nasopharyngeal Carcinoma, sponsored by Ming-Yuan Chen. Recruiting at 6 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Primary conditionNasopharyngeal CarcinomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Carcinoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Nasopharyngeal Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ming-Yuan Chen · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing nimotuzumab in Nasopharyngeal Carcinoma — 7 open to participants now, 10 under way, 4 of them phase 3. nimotuzumab · Nasopharyngeal Carcinoma.

Planned enrollment
9th of 17
208 · median 208
Started
2025
with 1 other
Phase 2
10 of 17
3 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Ming-Yuan Chen

Among the 17 studies testing nimotuzumab in Nasopharyngeal Carcinoma, this one is the 9th largest by planned enrollment, is one of 2 that started in 2025, is one of 10 in phase 2, and was the 16th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

7 of the 17 studies testing nimotuzumab in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About nimotuzumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing nimotuzumab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy.

The four treatment arms include:

  1. Ivonescimab monotherapy,
  2. Ivonescimab combined with nimotuzumab,
  3. Liposomal mitoxantrone plus anti-PD-1 antibody, and
  4. Liposomal irinotecan plus S-1.
Read the detailed description

Patients with recurrent (not amenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have progressed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy are eligible for this study. This trial adopts a Bayesian Adaptive Randomization with Constant Power parameter (BARCP) design. The planned maximum sample size is 208 patients, with a minimum of 32 patients to be enrolled before potential early termination for futility or efficacy based on interim analysis.

The first 40 patients will be randomized with equal probability to one of the four treatment arms:

  1. Ivonescimab monotherapy
  2. Ivonescimab combined with nimotuzumab
  3. Liposomal mitoxantrone plus an anti-PD-1 antibody
  4. Liposomal irinotecan plus S-1

Subsequent randomization probabilities will be updated based on objective response rate (ORR) using interim analyses, which will include decisions for early efficacy, futility, or reassignment of allocation probabilities for future participants. Interim analyses will be conducted every time 16 new patients complete ORR assessment. The minimum allocation probability for each treatment arm is constrained to 5%.

All patients will receive treatment until disease progression (as determined by the investigator based on RECIST 1.1 criteria), intolerable toxicity, withdrawal of informed consent, initiation of new anticancer therapy, loss to follow-up, death, or study completion-whichever occurs first. Regular visits and imaging assessments will be conducted to evaluate the efficacy and safety of the treatment regimens.

03

Conditions studied

  • Recurrent or Metastatic Nasopharyngeal Carcinoma

Browse trials for

Keywords

  • nasopharyngeal carcinoma
  • Recurrent
  • metastatic
  • PD-1 resistance
  • Bayesian adaptive design
  • Ivonescimab
  • Nimotuzumab
  • Liposomal mitoxantrone
  • Liposomal irinotecan
  • S-1
04

In context

Nasopharyngeal Carcinoma Reclassified

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

This study's planned enrollment of 208 is above the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.

Browse Nasopharyngeal Carcinoma studies →

Lead sponsor

Ming-Yuan Chen is the lead sponsor of 12 studies on the registry; 12 are open to participants now.

Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. and/or cytologically confirmed recurrent or non-keratinizing nasopharyngeal carcinoma (either differentiated or undifferentiated subtype, corresponding to WHO type II or III).
  2. Age between 18 and 70 years.
  3. Performance Status (PS) score of 0 or 1.
  4. Disease progression after prior platinum-based doublet chemotherapy.
  5. Received at least one previously. (Progression occurring during or within 6 months after definitive concurrent chemoradiotherapy, /adjuvant therapy, or treatment completion may be counted as first-line treatment.)
  6. Resistance to antibody therapy (either combination or sequential), including primary or secondary resistance(PD-1 exposure must be at least 6 weeks.)
  7. At least one according to 1.1 criteria.
  8. All acute toxicities from prior anti-tumor therapies have resolved to grade ≤1 (per v5.0) or meet the specified inclusion/exclusion thresholds. (Certain toxicities such as alopecia, hair color changes, nail changes, fatigue, etc., which do not pose safety risks, are exempt.)
  9. Adequate organ function:

    Hematology: WBC ≥ 4000/μL, ≥ 2000/μL, ≥ 9 g/dL, ≥ 100,000/μL.

    Liver function: Total ≤ 1.5 × (ULN) (patients with Gilbert's syndrome and bilirubin ≤ 3 × ULN are eligible); and ALT ≤ 3 × ULN; alkaline phosphatase ≤ 3 × ULN; albumin ≥ 3 g/dL.

    Coagulation: , prothrombin time (PT), or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.

    Renal function: Serum creatinine ≤ 1.5 × ULN or ≥ 60 mL/min calculated by Cockcroft-Gault formula. Proteinuria: Urine protein/creatinine ratio (UPC) \< 1.0. For UPC ≤ 0.5, no further testing is required; for UPC > 0.5, 24-hour urine protein must be \< 1000 mg for eligibility.

  10. Estimated of at least 3 months.
  11. Signed and willingness and ability to comply with study visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Locoregional recurrent lesions that are amenable to definitive (curative) treatment, such as surgery.
  2. Prior treatment with any regimen included in the study protocol.
  3. Prior use of agents targeting the VEGF or VEGFR pathway.
  4. Diagnosis and/or treatment of another within the past 5 years, with the exception of adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.
  5. Receipt of surgery, chemotherapy, radiotherapy, immunotherapy, any agent, or other anti-cancer therapy within 4 weeks prior to enrollment (or within 2 weeks for palliative radiotherapy).
  6. Tumor encasement of the internal carotid artery or evidence of nasopharyngeal necrosis observed on endoscopy prior to enrollment.
  7. Any significant bleeding event (≥ Grade 2, v5.0) within 4 weeks prior to enrollment, or visible hemoptysis defined as ≥ 1/2 teaspoon of fresh red blood or blood clots with little or no sputum. Recurrent positive fecal occult blood test (++ or more) during screening also leads to exclusion. (Patients with occasional blood-tinged sputum may be eligible.)
  8. Active peptic ulcers or gastrointestinal surgery within 1 month prior to enrollment; history within 6 months of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, gastrointestinal hemorrhage, esophageal varices, or pathological fracture.
  9. Uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg) despite antihypertensive therapy; coronary artery disease ≥ Grade II; or any of the following within 6 months prior to enrollment: myocardial infarction, severe or unstable angina, class II or higher heart failure, sustained arrhythmia ≥ Grade 2 (including >450 ms in males or >470 ms in females), atrial fibrillation of any grade, coronary or peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular events (e.g., or symptomatic pulmonary embolism). History of arterial thromboembolism or venous thromboembolism > Grade 3. (ST elevation ≥2 mm on without clinical evidence of myocardial infarction or ischemia is not exclusionary.)
  10. History of bleeding diathesis, hemorrhagic disorders, or coagulopathy; current use of anticoagulants or antiplatelet agents including warfarin, heparin, aspirin >325 mg/day, ticlopidine, clopidogrel, or cilostazol, unless discontinued ≥10 days prior to first dose and coagulation parameters meet inclusion criteria.
  11. Severe infection requiring intravenous antibiotics, antifungals, or antivirals within 4 weeks prior to the first dose, or unexplained fever >38.5°C within 7 days prior to the first dose; baseline WBC >15 × 10⁹/L.
  12. Known to study drugs or , or a history of severe hypersensitivity reactions such as generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis.
  13. Conditions that may affect oral drug absorption, including dysphagia, nausea/vomiting, chronic diarrhea, or bowel obstruction.
  14. Ongoing treatment with or systemic (>10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose.
  15. Presence of any active disease or a history of autoimmune diseases likely to recur (including but not limited to interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism). Exceptions include vitiligo and childhood asthma now in complete remission. Patients with asthma requiring bronchodilator therapy are excluded.
  16. History of acute exacerbation of or other respiratory disease requiring hospitalization within 1 month prior to enrollment; patients with active tuberculosis or those who received anti-TB therapy within 1 year prior to screening.
  17. positive; or positive with quantifiable HBV DNA ≥1000 cps/mL; or positive anti- antibody.
  18. Receipt of within 4 weeks prior to first dose or anticipated during the study period.
  19. Positive pregnancy test or currently breastfeeding.
  20. Women of or sexually active men who are unwilling or unable to use medically accepted methods of during the study period.
  21. Any condition, as determined by the investigator, that may interfere with the study results or patient safety, such as substance abuse, serious physical or mental illness requiring concurrent treatment, significant laboratory abnormalities, or adverse social/family circumstances.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Ivonescimab Monotherapy

    Participants will receive Ivonescimab at a dose of 10 mg/kg via intravenous infusion, Q3W. Treatment will continue until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

    Drug: Ivonescimab

  • Experimental
    Ivonescimab plus Nimotuzumab

    Participants will receive Ivonescimab at a dose of 10 mg/kg via intravenous infusion, combined with Nimotuzumab 400 mg via intravenous infusion, Q3W. Treatment will continue until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

    Drug: Ivonescimab · Drug: Nimotuzumab

  • Experimental
    Mitoxantrone Plus PD-1 Inhibitor

    Participants will receive mitoxantrone hydrochloride liposome at 20 mg/m² via intravenous infusion, combined with a PD-1 inhibitor - either tislelizumab (200 mg/cycle), camrelizumab (200 mg/cycle), or toripalimab (240 mg/cycle) - Q3W, for up to 8 cycles. After combination therapy, participants will continue receiving PD-1 blockade monotherapy every 3 weeks for up to 2 years, or until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

    Drug: Mitoxantrone Hydrochloride Liposome · Drug: PD-1 Inhibitors

  • Experimental
    Irinotecan plus S-1

    Participants will receive liposomal irinotecan at 50 mg/m² via intravenous infusion on D1 and D15, Q4W, in combination with oral S-1 administered BID on D 1-14 of each cycle, for up to 6 cycles. The dose of S-1 is based on body surface area (BSA). BSA \< 1.25 m²: 40 mg per dose ; 1.25 m² ≤ BSA \< 1.5 m²: 50 mg per dose; BSA ≥ 1.5 m²: 60 mg per dose Treatment will continue until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

    Drug: Irinotecan liposome · Drug: S-1

Interventions

  • Ivonescimab 10 mg/kg via intravenous infusion, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

  • Nimotuzumab 400 mg via intravenous infusion, Q3W, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.

  • DrugIrinotecan sucrosofateStudies of Irinotecan sucrosofateIrinotecan sucrosofate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Irinotecan liposome 50mg/m2 via intravenous infusion, D1, D15, Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.

  • DrugS-1

    Drug pages: TegafurStudies of TegafurTegafur pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GimeracilStudies of GimeracilGimeracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Oxonic AcidStudies of Oxonic AcidOxonic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    S-1, D1-D14, BID, p.o., (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose), Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.

  • DrugLiposomal Mitoxantrone HydrochlorideStudies of Liposomal Mitoxantrone HydrochlorideLiposomal Mitoxantrone Hydrochloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mitoxantrone hydrochloride liposome 20mg/m2 via intravenous infusion, Q3W for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) , Q3W for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Defined as the proportion of patients whose tumors shrink to complete response (CR) or partial response (PR) and remain for a certain period of time according to RECIST 1.1

    Time frame: 1 year

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time interval from randomization to the observation of disease progression or death from any cause

    Time frame: 1 year

  2. Overall Survival (OS)

    OS is defined as the time interval from randomization to death from any cause

    Time frame: 1 year

  3. Duration of Response (DOR)

    DOR is defined as time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death

    Time frame: 1 year

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of patients who have achieved CR, PR and SD to a therapeutic intervention

    Time frame: 1 year

  5. Adverse Events Reporting

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 1 year

  6. Health-related Quality of Life

    Changes from baseline in patient-reported quality of life scores assessed every 2 cycles using the EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, version C30). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome.

    Time frame: 1 year

  7. Head and Neck Cancer-Specific Quality of Life

    Changes from baseline in head and neck cancer-specific symptoms and functions assessed every 2 cycles using the EORTC QLQ-H\&N35 module (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Head and Neck Cancer Module). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome and lower scores indicating worse symptoms or functions.

    Time frame: 1year

08

Study locations

1 of 6 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Data can be requested from the corresponding author beginning 1 year after publication of the study.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 19 months is below that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 17, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2028
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07070479
Lead sponsor
Ming-Yuan Chen
Responsible party
Ming-Yuan Chen (Professior, Chief physician, Sun Yat-sen University) — Sponsor-investigator
First posted
Jul 17, 2025
Start date
Jun 24, 2025
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Sep 18, 2025

Study contacts

Mingyuan Chen
Contact
chmingy@mail.sysu.edu.cn
+86 18124188280

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Nimotuzumab · Irinotecan sucrosofate · Tegafur · Gimeracil · Oxonic Acid · Immune checkpoint inhibitors

Start the discussion